LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-16. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
== Technology and products == Theranos claimed to have developed devices to automate and miniaturize blood tests using microscopic blood volumes. Theranos dubbed its blood collection vessel the "nanotainer" and its analysis machine the "Edison". Holmes reportedly named the device "Edison" after inventor Thomas Edison, stating, "We tried everything else and it failed, so let's call it the Edison." Refinery29 posited that this was because of a well-known Edison quote: "I've not failed. I've just found 10,000 ways that won't work." The blood sample was to be collected via a finger prick and then transferred to the nanotainer through Theranos's sample collection device. At just 12.9 millimetres (0.51 in) in height, the nanotainer held a couple of drops of blood. One of the patents for the Edison described a point of care system that could communicate with the Internet to receive instructions for which blood tests to run on the samples, before communicating these results back through the Internet. The results would then be compared to medical data available on the Internet, with the Edison running supplementary blood tests that were more targeted based on the results of the comparison. The patent was unclear on how much blood the Edison would actually require to conduct these blood tests. In one section, the patent claimed the sample needed to consist of about 10 drops of blood, but in another section, it claimed the Edison would need less than one drop of blood. The technology was criticized for not being peer reviewed.
==== Absorption ==== The oral bioavailability of atenolol is approximately 50 to 60%. The absorption of atenolol with oral administration is rapid and consistent but is incomplete. About 50% of an oral dose of atenolol is absorbed from the intestines, with the rest excreted in feces. Maximal concentrations of atenolol occur 2 to 4 hours following an oral dose, whereas peak concentrations occur within 5 minutes with intravenous administration. The pharmacokinetic profile of atenolol results in it having relatively consistent plasma drug levels with about 4-fold variation between individuals.
Ultimately, due to known side-effects of sirolimus, as well as inadequate evidence for optimal dosing, it was concluded in 2016 that more research was required before sirolimus could be widely prescribed for this purpose. Two human studies on the effects of sirolimus (rapamycin) on longevity did not show statistically significant benefits. However, due to limitations in the studies, further research is needed to fully assess its potential in humans. Sirolimus has complex effects on the immune system—while IL-12 goes up and IL-10 decreases, which suggests an immunostimulatory response, TNF and IL-6 are decreased, which suggests an immunosuppressive response. The duration of the inhibition and the exact extent to which mTORC1 and mTORC2 are inhibited play a role, but were not yet well understood according to a 2015 paper.
Sources: en.wikipedia.org
mutator gene Any mutant gene or sequence that increases the spontaneous mutation rate of one or more other genes or sequences. Mutators are often transposable elements, or may be mutant housekeeping genes such as those that encode helicases or proteins involved in proofreading.
Tolkien arrived at the Somme in early July 1916. In between terms behind the lines at Bouzincourt, he participated in the assaults on the Schwaben Redoubt and the Leipzig salient. Tolkien's time in combat was a terrible stress for Edith, who feared that every knock on the door might carry news of her husband's death. Edith could track her husband's movements on a map of the Western Front. The Reverend Mervyn S. Evers, Anglican chaplain to the Lancashire Fusiliers, recorded that Tolkien and his fellow officers were eaten by "hordes of lice" which found the Medical Officer's ointment merely "a kind of hors d'oeuvre and the little beggars went at their feast with renewed vigour." On 27 October 1916, as his battalion attacked Regina Trench, Tolkien contracted trench fever, a disease carried by lice. He was invalided to England on 8 November 1916.
=== Response to injury === Myomesin has also been shown to play a role in injury response and expression. It was previously thought that myosin chaperones were the first alert of sarcomere damage, but recent studies show a flux of expression the gene myomesin1a much earlier than that of the myosin, suggesting that there is a myomesin-dependent injury response pathway in striated muscles. Additionally, it is thought that this gene could be used as an enhanced biomarker for sarcomere damage compared to the current biomarker, muscle creatine kinase (CKM). When tested in vivo in zebrafish, myom1a expression was displayed much earlier than creatine kinase, indicating that the latter is less specific to muscle diseases. This supports the use of myomesin assays for detection of muscular pathologies earlier than the current practices.
Sources: en.wikipedia.org
=== Use of confidentiality agreements === A New York Times investigation revealed that Johnson used confidentiality agreements to control his public image and that of his companies. Some of his workers have joined forces to challenge those agreements. Johnson defended his use of confidentiality agreements on social media, saying "I post nudes on social media. I track my nighttime erections. My team openly discusses my semen health... Rather than letting people walk in blind, we disclose this upfront, in writing, so there are no surprises."
== History == Sean Vanaman and Jake Rodkin were both at Telltale Games as co-writers on the 2012 game The Walking Dead, which was considered Telltale's first turn into a more narrative type of episodic adventure game. The game was a critical success, and while other projects came along, Vanaman started to become too comfortable with his role at Telltale, and felt that he would be more motivated if there was more discomfort or risk in his duties. After talking about the idea with Rodkin, the two left the company and co-founded Campo Santo on September 18, 2013, joined by Mark of the Ninja designer Nels Anderson and graphic artist Olly Moss. Environment artist Jane Ng and designer and composer Chris Remo, who had also worked with Vanaman and Rodkin on the Idle Thumbs podcast, soon joined the team as well. Soon after, they announced Panic would back their debut project. After a painting by Moss, Ng adapted the painting's aesthetic style into a 3D environment with the color and inspiration drawn from both New Deal advertisements and icons from the National Park Service as well as a camping trip in Yellowstone National Park in which the team visited a preserved fire lookout tower two miles (3.2 km) from the campsite. Development eventually led to the announcement of Firewatch in March 2014, with release originally slated for 2015. In August 2014, a game demo of Firewatch was released at PAX West, revealing the overall plotline and story of a fire lookout named Henry in the Shoshone National Forest in 1989.
Alpha decay or α-decay is a type of radioactive decay in which an atomic nucleus emits an alpha particle (helium nucleus). The parent nucleus transforms or "decays" into a daughter product, with a mass number that is reduced by four and an atomic number that is reduced by two. An alpha particle is identical to the nucleus of a helium-4 atom, which consists of two protons and two neutrons. For example, uranium-238 undergoes alpha decay to form thorium-234. While alpha particles have a charge +2 e, this is not usually shown because a nuclear equation describes a nuclear reaction without considering the electrons – a convention that does not imply that the nuclei necessarily occur in neutral atoms. Except for beryllium-8 (which decays to two alpha particles), alpha decay typically occurs in the heaviest nuclides. Theoretically, it can occur only in nuclei somewhat heavier than nickel (element 28), where the overall binding energy per nucleon is no longer a maximum and the nuclides are therefore unstable toward spontaneous fission-type processes. In practice, this mode of decay has only been observed in nuclides considerably heavier than nickel, with the lightest known alpha emitter (other than beryllium-8) being the second lightest isotope of antimony, 104Sb. Alpha decay is by far the most common form of cluster decay, where the parent atom ejects a defined daughter collection of nucleons, leaving another defined product behind. It is the most common form because of the combined extremely high nuclear binding energy and relatively small mass of the alpha particle.
==== Incremental ==== An incremental backup stores data changed since a reference point in time. Duplicate copies of unchanged data are not copied. Typically a full backup of all files is made once or at infrequent intervals, serving as the reference point for an incremental repository. Subsequently, a number of incremental backups are made after successive time periods. Restores begin with the last full backup and then apply the incrementals. Some backup systems can create a synthetic full backup from a series of incrementals, thus providing the equivalent of frequently doing a full backup. When done to modify a single archive file, this speeds restores of recent versions of files.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.